

Retraction

RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β -Catenin Downregulation and AMPK Activation. *Pharmaceutics* 2021, 13, 330

Shiwei Zhou ^{1,2,3,†} , Obinna N. Obianom ^{2,†}, Jiangsheng Huang ³, Dong Guo ², Hong Yang ², Qing Li ^{1,*}  and Yan Shu ^{1,2,*}

¹ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China

² Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA

³ Department of Thyroid Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China

* Correspondence: liqing9251026@csu.edu.cn (Q.L.); yshu@rx.umaryland.edu (Y.S.)

† These authors contribute equally to the work.

The authors and the journal retract the article, ‘Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β -Catenin Downregulation and AMPK Activation’ [1].

Following publication, the authors contacted the journal’s Editorial Office regarding two sets of mistakenly duplicated figures: Figure 3E is a copy of Figure 3D, and the loading control of Figure 4D is a copy of Figure 5A’s loading control.

Adhering to the journal complaints procedure, an investigation was conducted. The authors were unable to locate the original gel image of Figure 4D’s loading control data. The authors, the Editorial Board, and the Editor-in-Chief have agreed that the findings are no longer reliable, and the article was therefore retracted.

This retraction was approved by the Editor-in-Chief of the journal *Pharmaceutics*.

The authors agreed to this retraction.



Citation: Zhou, S.; Obianom, O.N.; Huang, J.; Guo, D.; Yang, H.; Li, Q.; Shu, Y. RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β -Catenin Downregulation and AMPK Activation. *Pharmaceutics* 2021, 13, 330. *Pharmaceutics* **2023**, *15*, 1623. <https://doi.org/10.3390/pharmaceutics15061623>

Received: 6 December 2022

Accepted: 7 February 2023

Published: 30 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Reference

1. Zhou, S.; Obianom, O.N.; Huang, J.; Guo, D.; Yang, H.; Li, Q.; Shu, Y. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β -Catenin Downregulation and AMPK Activation. *Pharmaceutics* **2021**, *13*, 330. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.